Identification of Stimulant Drugs by Surface-Enhanced Raman Spectrometry on Colloidal Silver

Total Page:16

File Type:pdf, Size:1020Kb

Identification of Stimulant Drugs by Surface-Enhanced Raman Spectrometry on Colloidal Silver Vibrational Spectroscopy, 2 (1991) 145-154 145 Elsevier Science Publishers B.V., Amsterdam Identification of stimulant drugs by surface-enhanced Raman spectrometry on colloidal silver A. RupCrez, R. Montes and J.J. Lasema * Department of Physical Chemistry and Department of Analytical Chemistry, Faculty of Sciences, Uniuersity of Ma’laga, 29071 Mrilaga (Spain) (Received 2nd February 1991) Abstract The surface-enhanced Raman (SER) spectra of stimulant drugs, including mefenorex, pentylenetetrazole, L- amphetamine and pemoline, were obtained on colloidal silver. Silver colloids are prepared in a single step, at room temperature, by chemical reduction of Ag+ with sodium tetrahydroborate. Spectra are recorded using drug concentrations at the pg ml-’ level. Individual drugs can be identified by characteristic vibrational bands. The SER spectrum of human urine and that of human urine spiked with mixtures of stimulant drugs are reported. Keywords: Raman spectrometry; Amphetamine; Mefenorex; Pemoline; Pentylenetetrazole; Pharmaceuticals; Sports doping; Stimulant drugs The increase over the last 30 years in the use In recent years, a number of papers have been of drugs in sport (doping) has led the Intema- published demonstrating the detectability of low tional Olympic Committee (IOC) to establish a molecule concentrations (< lop4 M) by adsorp- list of banned substances and to introduce formal tion on rough metal surfaces and subsequent drug testing. The doping classification includes Raman scattering [surface-enhanced Raman scat- stimulants as one of the five regulated categories. tering (SERS)]. Raman spectra of substances at Stimulants include various types of drugs which trace concentrations are readily obtained [6-l 11, increase alertness, competitiveness and hostility even in the presence of a strong luminescence and reduce fatigue. Stimulants also produce a background. Luminescence from adsorbed species false sense of ability and may cause a loss of is generally quenched by radiationless energy judgement, leading to accidents within sports. transfer to the metal surface [12-141. The first These include irregular heart rate, which may enhancement of Raman signals by adsorption on lead to cardiac arrest, the development of para- a rough metal surface was observed in 1974 [15], noid psychosis, a rise in body temperature, which the SER spectrum of pyridine on electrochemi- can induce dehydration in warm weather, and the tally roughened silver electrodes being obtained. masking of fatigue, which can lead to circulatory Since then, different metals have been reported collapse, heart exhaustion and stroke. to be SER-active, including silver, gold, copper The determination of stimulants in urine (the and, to a lesser extent, platinum, nickel, indium sample of choice in doping control) is accom- and others. Diverse roughening procedures have plished using a variety of techniques including gas been also investigated for the production of ac- chromatography [l], liquid chromatography [2,3] tive surfaces 116,171. Excitation with red wave- and gas chromatography mass spectrometry [4,5]. lengths is a requirement for large enhancement 0924-2031/91/$03.50 0 1991 - Elsevier Science Publishers B.V. All rights reserved 146 A.RUPkREZETAL. factors using gold and copper as substrates [18,191. mineralized water was used throughout. Mefeno- However, most visible wavelengths can be used rex, pentylenetetrazole, L-amphetamine and pe- with silver. For chemical characterization, col- moline were purchased from Sigma. Stock aque- loidal silver seems to be the most amenable sub- ous solutions (100 pg ml-‘) contained about 5% strate in terms of production, storage and sample methanol to help dissolve the drugs. Silver hydro- handling, although difficulties with the repro- sols were prepared at room temperature in test ducibility of SERS intensities have been reported tubes by adding 1 ml of 1.0 x 10e3 M AgNO, to La. 3 ml of 2.0 x 10e3 M NaBH,. Hydrosols so pre- A few papers [21,22] on the applicability of the pared showed an absorption maximum at 380 nm SERS technique to biological samples are avail- with no other spectral features in the long-wave- able. This whole demonstrates the analytical use- length side of this band. Each sample was pre- fulness of SERS for the identification of drugs in pared by adding 0.1 ml of the drug solution to 3 human urine samples using a silver hydrosol as a ml of the silver colloid at room temperature. substrate. The SER spectrum of urine and those After mixing, the resulting test solution was of urine spiked with four stimulants were ob- transferred into the liquid cell and placed in the tained. The procedure is easy to perform and the sample chamber of the spectrometer. The SER drugs can be readily identified by characteristic spectra of urine were obtained by spiking 0.1 ml bands in the SER spectrum of spiked urine. of unfiltered urine with 0.1 ml of drug solution and adding the resulting sample to 3 ml of silver colloid at room temperature. Urine samples were EXPERIMENTAL taken from healthy human subjects. Instrumentation The Raman system has been described in a RESULTS AND DISCUSSION previous paper [231. Basically, it consisted of a helium-neon laser (Siemens, Model LGK 76268) The SER spectra of mefenorex, pentylenete- tuned at 632.8 nm. The power at the sample was trazole, L-amphetamine and pemoline on silver typically 30 mW. Spectra were obtained with a colloid are shown in Fig. 1. Table 1 summarizes 0.22-m double-grating spectrometer (Spex Indus- the vibrational bands of these substances and tries, Model 1680B). The Raman scattering was shows selective spectral features corresponding to collected at right-angles and detected with a ther- the presence of different heteroatoms and sub- moelectrically cooled photomultiplier tube stituent groups on the ring systems. The peak (Hamamatsu, Model R928) and a photon count- positions of the conventional Raman (CR) spec- ing system (Stanford Research, Model SR 400). tra of the pure drugs (liquid state for L- Data acquisition, storage, processing and plotting amphetamine and solid state for the others) also were controlled by an IBM AT compatible micro- are listed in Table 1. computer. All spectra reported represent single The SER spectrum of mefenorex shows two scans and are provided with spectral smoothing medium bands at 990 and 651 cm-i and a weak of 11 or 17 points (Savitzky-Golay algorithm). mode at 1580 cm-‘, which appears in the CR The time constant of the detection electronics spectrum at 1598 cm-‘. The band at 651 cm-‘, was 0.3 s and each spectrum consisted of 968 data also appearing in the CR spectrum, can be at- points. Frequencies were accurate to within 3 tributed to the interaction of bending mode of cm-’ for strong, sharp bands. The spectrometer the carbon atoms in positions 1 and 4 with the resolution was generally set to 14 cm-‘. stretching of the bond connecting the substituent to the ring [24]. The C-X distance increases as Chemicals and procedure the distance between C-l and C-4 decreases. The All chemicals were of analytical-reagent grade band at 990 cm-’ corresponds to in-plane ring or equivalent, and were used as received. De- deformation. 147 SERS OF STIMULANT DRUGS - CH,CH(CH,)NH(CH,),CI / Q- a00 ,200 Raman shift (cm-‘) Raman shift (cm-‘) L-omphetamlne 1 I 800 lma Isc4 Roman shift (cm-‘) Fig. 1. Surface-enhanced Raman spectra of stimulant drugs on colloidal silver. Drug concentration, 25 fig ml-’ on the measured sample. 148 A. RUPl?REZ ET AL. The SER spectrum of pentylenetetrazole shows appears at 1580 cm-‘, probably due to the pres- a medium band at 1029 cm-’ and weak bands at ence of the C=N bond. Pemoline also exhibits a 674, 950, 1095, 1130, 1150 and 1584 cm-‘. Sev- medium band at 658 cm-’ and a strong band at eral other weak vibrational modes occur between 830 cm-‘. 1150 and 1550 cm-r and a medium band at 1640 The CR spectrum of mefenorex (Fig. 2) shows cm-‘. a strong band at 828 cm-’ which appear in the The SER spectrum of L-amphetamine shows SER spectrum as a weak band at 820 cm-‘. The the characteristic vibrational modes of the ben- medium band at 1379 cm- ’ could be due to zene ring at 990 and 1012 cm-’ and two modes at symmetric CH, deformation. Also, it exhibits 1112 and 1174 cm-‘, which may be due to the medium bands at 651, 1165 and 1316 cm-‘. Fig- primary amine group with a tertiary a-carbon ure 2c shows the CR spectrum of pentylenetetra- atom. A medium band at 1645 cm- ’ may be due zole, with the most prominent peaks at 1650 and to NH, bending. 661 cm-‘. Several weak bands occur in the spec- The SER spectrum of pemoline exhibits abun- tral zone examined. The weak SER band at 1385 dant spectral features. Medium bands at 1014 cm-’ appears in the CR spectrum at 1370 cm-‘. and 1047 cm-’ are observed. The medium band L-amphetamine (Fig. 2) shows a strong peak at at 1170 cm-’ and the very strong peak at 1640 990 cm-’ with a shoulder at 1012 cm-’ and weak cm-’ may be due to C-N stretching of the amine bands at 456, 493 and 821 cm-‘. These bands group [25] and NH, bending, respectively. The appear as weak vibrational modes in the SER weak band at 1745 cm-’ may be attributed to spectrum at similar Raman shifts. The other bands carbonyl group stretching. Another strong band in the CR spectrum also appear in the SER TABLE 1 Observed surface-enhanced Raman shifts (SERS, cm-‘) on colloidal silver, conventional Raman shifts (CRS, cm-‘) and relative peak intensities (in parentheses, on a semiquantitative scale from 1 to 10) of stimulant drugs L-Amphetamine
Recommended publications
  • The Stimulants and Hallucinogens Under Consideration: a Brief Overview of Their Chemistry and Pharmacology
    Drug and Alcohol Dependence, 17 (1986) 107-118 107 Elsevier Scientific Publishers Ireland Ltd. THE STIMULANTS AND HALLUCINOGENS UNDER CONSIDERATION: A BRIEF OVERVIEW OF THEIR CHEMISTRY AND PHARMACOLOGY LOUIS S. HARRIS Dcparlmcnl of Pharmacology, Medical College of Virginia, Virginia Commonwealth Unwersity, Richmond, VA 23298 (U.S.A.) SUMMARY The substances under review are a heterogenous set of compounds from a pharmacological point of view, though many have a common phenylethyl- amine structure. Variations in structure lead to marked changes in potency and characteristic action. The introductory material presented here is meant to provide a set of chemical and pharmacological highlights of the 28 substances under con- sideration. The most commonly used names or INN names, Chemical Abstract (CA) names and numbers, and elemental formulae are provided in the accompanying figures. This provides both some basic information on the substances and a starting point for the more detailed information that follows in the individual papers by contributors to the symposium. Key words: Stimulants, their chemistry and pharmacology - Hallucinogens, their chemistry and pharmacology INTRODUCTION Cathine (Fig. 1) is one of the active principles of khat (Catha edulis). The structure has two asymmetric centers and exists as two geometric isomers, each of which has been resolved into its optical isomers. In the plant it exists as d-nor-pseudoephedrine. It is a typical sympathomimetic amine with a strong component of amphetamine-like activity. The racemic mixture is known generically in this country and others as phenylpropanolamine (dl- norephedrine). It is widely available as an over-the-counter (OTC) anti- appetite agent and nasal decongestant.
    [Show full text]
  • The 2014 Prohibited List International Standard
    The World Anti-Doping Code THE 2014 PROHIBITED LIST INTERNATIONAL STANDARD Version 2.0 (revised 2014 version) The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 September 2014 The revised 2014 Prohibited List 17 May 2014 THE 2014 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 September 2014 In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-androstenedione (5α- androst-1-ene-3,17-dione); bolandiol (estr-4-ene-3β,17β-diol ); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol;
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No
    Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No. Description Base Rate Staging 0101 Live horses, asses, mules and hinnies: 0101.10.00 -Purebred breeding animals Free E 0101.90 -Other: 0101.90.10 --Horses Free E 0101.90.20 --Asses 6.8% B --Mules and hinnies: 0101.90.30 ---Imported for immediate slaughter Free E 0101.90.40 ---Other 4.5% A 0102 Live bovine animals: 0102.10.00 -Purebred breeding animals Free E 0102.90 -Other: 0102.90.20 --Cows imported specially for dairy purposes Free E 0102.90.40 --Other 1 cent/kg A 0103 Live swine: 0103.10.00 -Purebred breeding animals Free E -Other: 0103.91.00 --Weighing less than 50 kg each Free E 0103.92.00 --Weighing 50 kg or more each Free E 0104 Live sheep and goats: 0104.10.00 -Sheep Free E 0104.20.00 -Goats 68 cents/head A 0105 Live poultry of the following kinds: Chickens, ducks, geese, turkeys and guineas: -Weighing not more than 185 g: 0105.11.00 --Chickens 0.9 cents each A 0105.12.00 --Turkeys 0.9 cents each A 0105.19.00 --Other 0.9 cents each A -Other: 0105.92.00 --Chickens, weighing not more than 2,000 g 2 cents/kg A 0105.93.00 --Chickens, weighing more than 2,000 g 2 cents/kg A 0105.99.00 --Other 2 cents/kg A 0106 Other live animals: -Mammals: 0106.11.00 --Primates Free E 0106.12.00 --Whales, dolphins and porpoises (mammals of the order Cetacea); manatees and dugongs (mammals of the order Sirenia) Free E 0106.19 --Other: 2B-Schedule-1 HTSUS No.
    [Show full text]
  • 124.210 Schedule IV — Substances Included. 1
    1 CONTROLLED SUBSTANCES, §124.210 124.210 Schedule IV — substances included. 1. Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. b. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane). c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Alprazolam. b. Barbital. c. Bromazepam. d. Camazepam. e. Carisoprodol. f. Chloral betaine. g. Chloral hydrate. h. Chlordiazepoxide. i. Clobazam. j. Clonazepam. k. Clorazepate. l. Clotiazepam. m. Cloxazolam. n. Delorazepam. o. Diazepam. p. Dichloralphenazone. q. Estazolam. r. Ethchlorvynol. s. Ethinamate. t. Ethyl Loflazepate. u. Fludiazepam. v. Flunitrazepam. w. Flurazepam. x. Halazepam. y. Haloxazolam. z. Ketazolam. aa. Loprazolam. ab. Lorazepam. ac. Lormetazepam. ad. Mebutamate. ae. Medazepam. af. Meprobamate. ag. Methohexital. ah. Methylphenobarbital (mephobarbital).
    [Show full text]
  • Doping Control of Athletes
    trends in analytical chemistry, vol. 7, no. IO, I988 375 trends Doping control of athletes E. G. de Jong*, I?. A. A. Maes and The definition of the Council of Europe for doping J. M. van Rossum is2: Utrecht, Netherlands ‘The administration to or the use by a healthy indi- vidual in any way of compounds which are not natu- History ral to the organism or the use of physiological com- The origin of the word doping is not certain. It first pounds in abnormal doses or in an abnormal way appeared in the English dictionaries at the end of the with the only purpose to artificially and dishonestly nineteenth century. The first reference to the use of influence the performance of this person during doping by athletes was in 1864 during swimming competition.’ competitions that were held in the canals of Amster- Another possible definition is: dam. The use of what is known as a ‘speedball’, a ‘The use of compounds which are not synthesized mixture of heroine and cocaine, by cyclists was de- by the human body or the use of endogenous com- scribed in 1869. In 1904 the Russian chemist pounds in excessive doses with the aim to improve Bukowski was able to identify some alkaloids in the performance in sport competitions.’ saliva of horses’. A simpler definition is: Australia was the first country to take measures ‘The use of forbidden drugs. ’ against doping in sports in 1962, and England fol- The last definition can only be used when we have lowed with the drugs bill in 1964.
    [Show full text]
  • Psychotropic Substances 2013
    Annexes Annexes Anexos Tables of reported statistics The tables in the present section contain the statistical information years 2008-2012 are presented. Tables for substances in Schedule IV on psychotropic substances in Schedules I-IV of the 1971 Convention contain data for the years 2010-2012 only. For technical reasons, furnished to INCB by Governments in accordance with article 16 of substances in Schedule IV were divided into the following five the Convention. As few Governments have reported the movement groups for the presentation of data on manufacture and international of substances listed in Schedule I, a brief statistical table, including trade: statistics on total manufacture of those substances for the three-year period 2010-2012 and on stocks of and international trade in those Group I: Central nervous system stimulants; substances for 2012, is provided. With regard to the statistical tables for substances in Schedules III and IV, it should be noted that, Group II: Anxiolytics, first part: although the majority of countries and territories reported on sub- main benzodiazepines and meprobamate; stances in all schedules, some Governments have not yet extended Group III: Anxiolytics, second part: the control measures of the 1971 Convention to all of the substances less common benzodiazepines; listed in Schedules III and IV. Therefore, for certain substances, the statistical data available to INCB may present only a partial picture Group IV: Benzodiazepines: of the global manufacture of and trade in those substances. sedative-hypnotics and anti-epileptics; With respect to substances in Schedules I and II, Governments Group V: Sedative-hypnotics and barbiturate-type are requested by INCB to report quantities in grams.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,365,521 B2 Blackburn Et Al
    USOO9365521B2 (12) United States Patent (10) Patent No.: US 9,365,521 B2 Blackburn et al. (45) Date of Patent: Jun. 14, 2016 (54) NON-HYGROSCOPICSALTS OF 5-HT, 5,178,786 A 1/1993 Jahnke et al. AGONSTS 5,247,080 A 9/1993 Berger et al. 5,275,915 A 1/1994 Kojima et al. 5,387,685 A 2f1995 Powell et al. (75) Inventors: Anthony C. Blackburn, San Diego, CA 5,397.793 A 3, 1995 Shaber et al. (US); Yun Shan, San Diego, CA (US); 5,412,119 A 5/1995 Brussee et al. Anna Shifrina, San Diego, CA (US); 5,422,355 A 6/1995 White et al. Scott Stirn, San Diego, CA (US) 5,691.362 A 11/1997 McCormicket al. 5,750,520 A 5/1998 Danilewicz et al. (73) Assignee: Arena Pharmaceuticals, Inc., San 5,856.5035,795,895 A 8,1/1999 1998 AnchAS al. Diego, CA (US) 5,861,393 A 1/1999 Danilewicz et al. 5,908,830 A 6/1999 Smith et al. (*) Notice: Subject to any disclaimer, the term of this 5,925,651 A 7/1999 Hutchinson patent is extended or adjusted under 35 3. A 3: As al U.S.C. 154(b) by 567 days. 5,958,943- 4 A 9/1999 Laufera etca. al. 6,087,346 A 7/2000 Glennon et al. (21) Appl. No.: 13/820,095 6,218,385 B1 4/2001 Adam et al. 6,900,313 B2 5/2005 Wasserscheid et al. (22) PCT Filed: Aug. 31, 2011 6,953,787 B2 * 10/2005 Smith .................
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • 2019 Prohibited List
    THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2019 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2019 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES NON-APPROVED SUBSTANCES Mestanolone; S0 Mesterolone; Any pharmacological substance which is not Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- addressed by any of the subsequent sections of the 3-one); List and with no current approval by any governmental Metenolone; regulatory health authority for human therapeutic use Methandriol; (e.g. drugs under pre-clinical or clinical development Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- or discontinued, designer drugs, substances approved androstan-3-one); only for veterinary use) is prohibited at all times. Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); ANABOLIC AGENTS Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- S1 androst-1-en-3-one); Anabolic agents are prohibited. Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); 1. ANABOLIC ANDROGENIC STEROIDS (AAS) Methyltestosterone; a. Exogenous*
    [Show full text]
  • Forensic Chemistry of Substance Misuse a Guide to Drug Control
    Forensic Chemistry of Substance Misuse A Guide to Drug Control Forensic Chemistry of Substance Misuse A Guide to Drug Control L. A. King ISBN: 978-0-85404-178-7 A catalogue record for this book is available from the British Library r L. A. King 2009 All rights reserved Apart from fair dealing for the purposes of research for non-commercial purposes or for private study, criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Society of Chemistry or the copyright owner, or in the case of reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the address printed on this page. Published by The Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge CB4 0WF, UK Registered Charity Number 207890 For further information see our web site at www.rsc.org Preface ‘‘Gold is worse poison to a man’s soul, doing more murders in this loathsome world, than any mortal drug’’ William Shakespeare (Romeo and Juliet) An earlier publication1 described the UK drugs legislation from the viewpoint of a forensic scientist. In the current book, an opportunity has been taken to rearrange and expand the material and improve clarity, to include the changes that have occurred in the past six years, and, more importantly, to widen the scope and the intended audience.
    [Show full text]